Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-290-6 | CAS number: 1319-46-6
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: chronic oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well-documented publication which meets basic scientific principles
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 985
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Trilead bis(carbonate) dihydroxide
- EC Number:
- 215-290-6
- EC Name:
- Trilead bis(carbonate) dihydroxide
- Cas Number:
- 1319-46-6
- Molecular formula:
- C2H2O8Pb3
- IUPAC Name:
- tris(λ²-lead(2+)) dihydroxide dicarbonate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 60 day old
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 1 year
- Frequency of treatment:
- ad libitum in diet
Doses / concentrations
- Remarks:
- Doses / Concentrations:
4 %
Basis:
nominal in diet
- Control animals:
- yes, plain diet
Examinations
- Observations and clinical examinations performed and frequency:
- OTHER: Both sciatic nerves
Time schedule: at 2, 4, 6, 8, 10, 12, 14 and 52 wk
Results and discussion
Results of examinations
- Neuropathological findings:
- effects observed, treatment-related
- Details on results:
- NEUROPATHOLOGY
The blood nerve-index (BNB) of rats exposed to lead was higher than that of pair-fed controls, and the difference increased within 52 wk
Any other information on results incl. tables
Because endoneurial protein changes are expected in lead neuropathy, it was important to determine if the elevated BNB-index was the result of a primary increase in endoneurial albumin concentration or of changes in endoneurial protein
Applicant's summary and conclusion
- Conclusions:
- It is clear that the elevated BNB-index was primarily the result of increased albumin concentration in the endoneurium of these lead-treated animals.The BNB-index can be used to evaluate blood-nerve barrier alterations quantitatively in animals models of neuropathy
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
